Treatment of chronic wounds represents a challenge for both the patient and modern healthcare systemsHow it works
To produce a durable closure for hard-to-heal wounds.
Treatment is non-invasive and easy to learn.
Healing of chronic wounds significantly decreases the financial burden of modern health care.
The underlying mechanism of action can be applied to different pathological conditions.
*The COMS® One therapy system is not cleared in the US.
We are a young company founded and based in Zurich, Switzerland since 2016. The Piomic family consists of biologists, engineers, entrepreneurs, designers, seniors and a broad group of supporters. Staffed with experts from different backgrounds and a common goal: By developing a therapy which is safe and effective, we want to set a better future for patients in need.More about us
In order to maximize our global impact, we are looking for investors who share our vision and wish to shape the future of wound care with us.Information for investors
03 Sep 2023
Trial seeks to assure Piomic’s COMS® treatment is safe and effective in therapy-refractory diabetic foot ulcersRead more
31 Aug 2023
CMS has approved the COMS One device for Category B designation and for Medicare coverage purposes during Piomic's IDE studyRead more
27 Apr 2023
Piomic Medical has received certificates according to MDR for its Class IIa and Class Is medical devices of the COMS® One Therapy System.Read more
10 Feb 2023
M&A experienced advanced wound care leader appointed as President of US Subsidiary Piomic Medical Inc.Read more